23 May 2013
Keywords: elan/biogen, idec, tysabri, maintains, remission, cd, patients
Article | 30 October 2006
Ireland's Elan and US drugmaker Biogen Idec say that 93% of Crohn's disease patients on their co-developed drug Tysabri (natalizumab), who
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 October 2006
13 November 2006
© 2013 thepharmaletter.com